

## A CFSE-based assay of proliferative response of lymphocytes to stimulation with dengue viruses

L. GIL<sup>1</sup>, R. ALONSO<sup>2</sup>, C. LÓPEZ<sup>1</sup>, A. BLANCO<sup>1</sup>, Y. ROMERO<sup>1</sup>, G. GUILLÉN<sup>1</sup>, L. HERMIDA<sup>1</sup>

<sup>1</sup>Division of Vaccines, Center for Genetic Engineering and Biotechnology (CIGB), P.O. Box 6162, Havana 10 600, Cuba;

<sup>2</sup>Department of Experimental Immunotherapy, Center of Molecular Immunology, Havana, Cuba

Received January 28, 2009; accepted June 22, 2009

**Summary.** – Dengue viruses (DENVs) are human pathogens that constitute a significant threat worldwide. Since they up-regulate MHC class I molecules; the cell-mediated immunity may play an important role in the defense against viruses. In this work, we tested a CFSE-based assay in determining proliferative response of lymphocytes isolated from mice or monkeys previously immunized with various DENV antigens to *in vitro* stimulation with DENVs. A positive proliferative response was obtained with lymphocytes of animals immunized with either live DENV-2 or its recombinant proteins. A similar result was also obtained with CD8+ T cells from mice immunized with live DENV-1 or DENV-2 following stimulation with homologous viruses. A comparison of the carboxyfluorescein diacetate succinimidyl ester (CFSE)-based and a <sup>3</sup>H-thymidine incorporation-based assays of proliferative response of total lymphocytes showed a fair correlation of results of both assays. However, the CFSE-based assay offers in addition the determination of contribution of the CD8+ or other subsets of T cells to total proliferative response. These results represent the first and successful application of a CFSE-based assay to the evaluation of cell-mediated immunity to DENVs. This assay might be also exploited in testing candidate DENV vaccines.

**Keywords:** cell-mediated immunity; CFSE, dengue viruses; lymphocytes; CD8+ T cells

### Introduction

DENVs including DENV-1 to DENV-4 (the genus *Flavivirus*, the family *Flaviviridae*) are transmitted to humans following a bite from an infected mosquito, usually *Aedes aegypti*. The infection may result in a disease of various severity, from asymptomatic to life-threatening syndrome, known as dengue hemorrhagic fever (DHF) (Gubler and Kuno, 1997). Epidemiological data suggest a greater risk of DHF during secondary infection and immunopathological mechanisms involved in this phenomenon (Vauhn *et al.*, 2000).

Antibody-dependent enhancement of secondary viral infections is a phenomenon that can explain the association between severe disease and preexisting immunity to DENV (Halstead, 1979). Other parameters such as viral load (Libraty *et al.*, 2002) and features of the virus and the host may also be important (Leitmeyer *et al.*, 1999; Gamble *et al.*, 2000; Loke *et al.*, 2001). Moreover, recent reports indicate that serotype cross-reactive memory T cells play an important role in the pathogenesis of the disease (Zivny *et al.*, 1999; Mongkolsapaya *et al.*, 2003, 2006; Beaumier *et al.*, 2008). However, dengue is a non-cytopathic virus that, similarly to other flaviviruses, up-regulates the expression of MHC class I molecules on the surface of infected cells (Cheng *et al.*, 2004; Lobigs *et al.*, 2004). Therefore, the cell-mediated immunity has been proposed as an important protection mechanism against DENV infections. Nevertheless, only a few studies have been reported on this topic (Gagnon *et al.*, 1996; Van der Most *et al.*, 2000).

Measurement of antigen-specific proliferative response is essential for assessment of cell-mediated immunity. Over

E-mail: lazaro.gil@cigb.edu.cu; fax: +537-2714764.

**Abbreviations:** CDI = cell division index; CFSE = carboxyfluorescein diacetate succinimidyl ester; CDI = cell division index; ConA = concanavalin A; DENV(s) = dengue virus(es); DHF = dengue hemorrhagic fever; PBMCs = peripheral blood mononuclear cells; SI = stimulation index

the last 30 years, this response has been measured by the incorporation of  $^3\text{H}$ -thymidine into the DNA of proliferating cells (Frome *et al.*, 1996). However, although the level of  $^3\text{H}$ -thymidine incorporation directly correlates with the number of cells that synthesize DNA during the pulse period, this method does not allow to detect proliferative responses of individual subsets of T cells. This problem can be circumvented by labeling cell population with CFSE prior to culture setup. CFSE reacts with secondary amino groups of intracellular proteins providing a uniform fluorescent label to cells (Lyons and Parish, 1994). Upon cell division a CFSE<sup>high</sup> cell loses half of its CFSE label and yields CFSE<sup>low</sup> daughter cells and these two cell populations can be differentiated by flow cytometry. Coupled to parallel analysis of other properties such as expression of surface molecules using specific fluorophore-conjugated antibodies, the CFSE-based assay provides additional information on proliferation profiles and differentiation.

In the present work, we evaluated the potential of a CFSE-based assay as an indirect measure of the cell-mediated immunity to DENVs. Using this assay, we (i) determined the proliferative response of lymphocytes or their CD8<sup>+</sup> subset isolated from different animals previously immunized with various DENV antigens to *in vitro* stimulation with live homologous virus, and (ii) compared the CFSE-based and  $^3\text{H}$ -thymidine incorporation assays in relation to proliferative response of total lymphocytes. This work constitutes the first report on use of a CFSE-based assay for determination of the proliferative response to *in vitro* stimulation with DENVs.

## Materials and Methods

**Viruses and recombinant viral proteins.** DENV-1 Jamaica strain and DENV-2 SB8553 strain (kindly provided by Dr. M.J. Cardosa, University of Sarawak, Kuching, Malaysia) were employed for *in vitro* stimulation of lymphocytes. Stock viruses were prepared from Vero cell cultures infected at a MOI of 10 PFU/cell in standard way. DENV-1 Hawaii strain and DENV-2 NGC strain passaged in suckling mice brain were used for immunization of mice. Viral titers were determined by plaque assay in BHK-21 cells. Recombinant DENV-2 capsid protein and DENV-2 PD5 protein (DENV-2 envelope fragment fused to the C-terminus of meningococcal P64k protein) were prepared by the Development Group of CIGB as described (López *et al.*, 2004, 2009).

**Preparation of lymphocytes.** Groups of five 6–8 week-old BALB/c mice (CENPALAB, Cuba) were inoculated intraperitoneally with DENV-1 Hawaii strain or DENV-2 NGC strain (one dose of  $10^4$  PFU/0.5 ml) or with recombinant DENV-2 capsid protein (3 doses of 10 µg at days 0, 15, and 30) as previously reported (Lazo *et al.*, 2007). A mock-inoculated group of mice served as negative control. Thirty days after the last dose, the animals were splenectomized under aseptic conditions. Lymphocytes were prepared from spleens in standard way.

A group of three American green monkeys (*Cercopithecus aethiops sabaues*) (CENPALAB, Cuba) were inoculated subcutaneously with recombinant DENV-2 proteins (four doses of 50 µg of capsid protein and 100 µg of PD5 protein at days 0, 30, 90, and 150). Another group inoculated with 100 µg doses of meningococcal P64k protein served as negative control. Blood was collected by venepuncture 15 days after the last dose and lymphocytes were isolated with Ficoll-Paque™ Plus (Amersham Biosciences AB, Sweden) by density gradient centrifugation.

**CFSE-based proliferation assay.** Lymphocytes were stained with CFSE (Molecular Probe, USA) as previously reported (Venken *et al.*, 2007). The stained cells were seeded in 96-well round-bottom plates ( $2 \times 10^5$  cells/well) in RPMI-1640 medium (Sigma) supplemented with 2 mmol/l glutamine,  $5 \times 10^{-5}$  mol/l 2-mercaptoethanol, 5% FBS and antibiotics. The cells were stimulated by adding DENV (0.05 PFU/cell) for 96 hrs. Mock-infected and concanavalin A (ConA, Sigma) -treated cells served as negative and positive controls, respectively. In all experimental series, triplicate wells were employed.

**Flow cytometry.** To assay proliferative response of total lymphocytes they were collected following stimulation, washed with PBS and subjected to flow cytometry in standard way. Dead cells were excluded by propidium iodide incorporation. Duplicate samples were analyzed in PasIII flow cytometer (Partec GmbH, Germany) using the WinMDI software version 2.8 (Purdue University, USA). Results were expressed as cell division index (CDI) defined as a ratio of the percentage of antigen-stimulated CFSE<sup>low</sup> cells to the percentage of antigen-unstimulated CFSE<sup>low</sup> cells. A response with  $\text{CDI} \geq 3$  and  $[\text{antigen-stimulated CFSE}^{\text{low}} \text{ cells} (\%)] - [\text{antigen-unstimulated CFSE}^{\text{low}} \text{ cells} (\%)] \geq 1$  was considered positive.

To assay proliferative response of CD8<sup>+</sup> T cells, lymphocytes were collected following stimulation, washed with PBS, stained with a PE-conjugated monoclonal antibody to CD8<sup>+</sup> T cells (BD Pharmingen, USA) and subjected to flow cytometry in standard way.

**$^3\text{H}$ -thymidine incorporation assay** was conducted as previously described (Jordan and Merigan, 1974; Lechmann and Liang, 2000). Briefly, lymphocytes ( $2 \times 10^5$ /well) were cultured in 96-well round-bottom plates with DENV-2 (0.05 PFU/cell) for 96 hrs. Mock-infected and ConA-exposed cells served as negative and positive controls, respectively. Results were expressed as SI defined as a ratio of the count of antigen-stimulated cells to the count of antigen-unstimulated cells.  $\text{SI} \geq 3$  was considered a positive result.

**Statistical analysis.** CDI and SI values were compared by the Pearson correlation test using the GraphPad Prism version 5.00 for Windows (GraphPad Software, USA) ([www.graphpad.com](http://www.graphpad.com)).

## Results

### *Proliferative response of lymphocytes from mice immunized with DENV-2 to in vitro stimulation with homologous virus as determined by the CFSE-based assay*

To assess the antigen-specific cell-mediated immunity in mice immunized with DENV-2 we determined their proliferative response to the virus *in vitro* by the CFSE-based assay (Table 1). As expected, DENV-2-immunized animals showed after 96 hrs of stimulation a positive proliferative

**Table 1. Proliferative response of lymphocytes from animals immunized with various DENV antigens to *in vitro* stimulation with homologous virus**

Immunization		Stimulation <i>in vitro</i> <sup>a</sup>	CDI			
Animals	Antigen		Lymphocytes		CD8+ T cells	
			Immunized animals	Non-immunized animals	Immunized animals	Non-immunized animals
Mice	DENV-2	DENV-2	5.05±1.06	1.6±0.28	–	–
	DENV-2 recomb. capsid protein		6.85±1.75	2.45±0.21	–	–
Monkeys	DENV-2 recomb. capsid and PD5 proteins		9.8±2.0	1.7±0.9	–	–
Mice	DENV-1	DENV-1	–	–	5.2±2.8	1.3±0.55
	DENV-2	DENV-2	–	–	5.6±1.5	1.8±0.94

<sup>a</sup>Lymphocytes were stimulated for 96 hrs.

response in contrast to negative response of non-immunized animals. A positive control with 5 µg/m ConA showed strong proliferative response. Similar results were obtained after 72 hrs but not 144 hrs, when an increased number of dead cells was observed (data not shown). Therefore, in further experiments a 96-hrs stimulation was used.

*Proliferative response of lymphocytes from mice immunized with recombinant DENV-2 capsid protein to *in vitro* stimulation with homologous virus as determined by the CFSE-based assay*

In the next experiment, a more defined system, in particular mice immunized with viral antigen instead of live virus were employed for testing the usefulness of the CFSE-based proliferation assay. As viral antigen a particulate recombinant DENV-2 capsid protein was chosen (López *et al.*, 2009). In general, recombinant proteins are expected to have a lower capacity to induce antigen-specific cell-mediated immunity as compared to that of live virus (Wang *et al.*, 1999). However, the chosen particulate antigen may be cross-presented by dendritic cells more efficiently than soluble antigen and consequently induce a fair antigen-specific cell-mediated immunity (Ackerman *et al.*, 2006). In the experiment, the mice immunized with the recombinant DENV-2 capsid protein generated lymphocytes proliferating strongly after virus stimulation *in vitro* (Table 1). Negative and positive controls gave expected results (data not shown).

*Proliferative response of lymphocytes from monkeys immunized with recombinant DENV-2 proteins to *in vitro* stimulation with homologous virus as determined by the CFSE-based assay*

To test the suitability of the CFSE-based proliferation assay for lymphocytes of different sources, monkeys were immunized with recombinant DENV-2 capsid and PD5

proteins and their PBMCs were stimulated *in vitro* with live DENV-2. The assay yielded a positive result for the lymphocytes from animals immunized with recombinant viral proteins and a negative result for the lymphocytes from non-immunized animals (Table 1). Positive control gave expected result (data not shown).

*Proliferative response of CD8+ T cells from mice immunized with DENV-1 or DENV-2 to *in vitro* stimulation with homologous viruses as determined by the CFSE-based assay*

Regarding the potential of the CFSE-based assay to determine individual subsets of proliferating cells, we selected CD8+ T cells. In this case, proliferative response of lymphocytes from mice immunized with DENV-1 or DENV-2 to *in vitro* stimulation with homologous viruses was assayed (Table 1). The results showed that CD8+ T cells from mice immunized with DENV-1 or DENV-2 gave a similarly strong proliferative response (Table 1). Negative and positive controls gave expected results (data not shown).

*Comparison of the CFSE-based and <sup>3</sup>H-thymidine incorporation assays of proliferative response of lymphocytes from mice immunized with DENV-2 and stimulated with homologous virus*

The previous experiments demonstrated the applicability of the CFSE-based assay to determination of the proliferative response of lymphocytes from two animal models immunized with different DENV antigens to *in vitro* stimulation with homologous live DENVs. Regarding the wide use of <sup>3</sup>H-thymidine incorporation assays in the field of DENVs (Kurane *et al.*, 1991; Rothman *et al.*, 1996) we compared the CFSE-based assay with this method. A number of samples of lymphocytes from mice immunized with DENV-2 stimulated with homologous virus were employed. As a result, both the




Fig. 1

Comparison of the CFSE-based (CDI) and the  $^3\text{H}$ -thymidine incorporation (SI) assays of proliferative response of lymphocytes from mice immunized with DENV-2 to stimulation with homologous virus

$^3\text{H}$ -thymidine incorporation and the CFSE-based assays gave the same positivity of proliferative response of lymphocyte samples, although SI values (the  $^3\text{H}$ -thymidine incorporation) were higher than CDI ones (the CFSE-based assay). However, a significant correlation between these values was detected ( $r = 0.9951$ ,  $p < 0.001$ ) (Fig. 1).

### Discussion

CFSE is a fluorescent dye that has been used to study cell division and other parameters such as surface expression of activation markers, cytokine and homing receptors, cytokine production, cytotoxic activity and indicators of apoptosis (Fazekas *et al.*, 1999). Also, different researchers have employed this method to measure the proliferative response to *in vitro* stimulation with specific antigens, e.g. proliferation of human lymphocytes after stimulation with tetanus toxoid (Mannering *et al.*, 2003; Venken *et al.*, 2007).

In this work, we used a CFSE-based assay to determine the proliferation of lymphocytes isolated from different animals, previously immunized with different DENV antigens, after stimulation with live homologous DENVs. Measuring a proliferative response to stimulation with live virus is highly important, particularly after immunization with subunit vaccine candidates. When live virus is used, viral epitopes are presented in a natural form, thus resembling a hypothetical *in vivo* boosting caused by a viral infection. However, lymphoproliferation assays are generally performed by stimulation with immunodominant peptides, which may overestimate the stimulatory capacity of the immunogen (Simmons *et al.*, 2005; Mongkolsapaya *et al.*, 2006).

First we measured by a CFSE-based assay the proliferative response of virus stimulated lymphocytes from mice immunized with DENV-2. In all cases, a positive response was detected. A similar result was published by Rothman *et al.* (1996), who stimulated lymphocytes from DENV-2-immunized mice with inactivated DENV-2. However, these experiments were done by using the  $^3\text{H}$ -thymidine incorporation assay.

When using a more rigorous system, mice immunized with recombinant DENV-2 capsid protein, we also found a proliferative response of lymphocytes after stimulation with homologous virus. This result is in accord with previous reports on CD4+ clones with cytotoxic activity specific for DENV-4 capsid protein (Gagnon *et al.*, 1996). However, the present work is the first report on a recombinant protein induction of a strong proliferative response to stimulation with homologous virus. This result could explain previous experimental evidences of protection of mice immunized with capsid protein without induction of neutralizing antibodies (Lazo *et al.*, 2007).

A proliferation response was also obtained with lymphocytes from monkeys co-immunized with DENV-2 capsid and PD5 proteins. This result confirmed the ability of the CFSE-based assay to measure proliferation of lymphocytes from different sources and represents the first report on determination of proliferative response to stimulation with a DENV in monkeys.

Additionally, we were able to detect a CD8+ T cell proliferative response after homologous virus stimulation in mice immunized with DENVs, demonstrating that the CFSE-based assay is essential for *in vitro* studies of the antigen-specific cell-mediated immunity in dengue. These results are consistent with those on other viruses reported previously (Svahn *et al.*, 2003). For example, a protective role of CD8+ T cells has been observed for influenza virus encephalitis in mice (Hawke *et al.*, 1998), lymphocytic choriomeningitis virus infection in mice (Williams *et al.*, 2006), and primary infection of mice with a neurotropic strain of mouse hepatitis coronavirus (Marten *et al.*, 2000). More recently, Yauch *et al.* (2009) have demonstrated a protective role of DENV-specific CD8+ T cells.

Summing up, our results demonstrate that the proliferative response measured by the CFSE-based assay correlates with that obtained by the  $^3\text{H}$ -thymidine incorporation assay. However, Mannering *et al.* (2003) reported that the CFSE-based assay was more sensitive than the  $^3\text{H}$ -thymidine incorporation assay in measuring the T cell proliferation from healthy donors in response to autoantigens. On the contrary, other researchers analyzing the correlation between activation markers on stimulated T cells and their proliferation concluded that both assays were complementary. Indeed, they recommended a combination of both methods to obtain a clear understanding of the events taking place in the

cell-mediated immune response (Caruso *et al.*, 1997). In the presented work, we did not observe any differences between the results of the two assays provided live DENV was used for stimulation purposes.

Analyzing the evidences described here, we can conclude that the CFSE-based assay is suitable for determining the proliferative response to live DENV-1 or DENV-2. Therefore, this method proves a powerful tool for further studies of the antigen-specific cell-mediated immunity to these flaviviruses. Moreover, it can be used to study T cell-mediated immunopathogenesis and develop new vaccine candidates.

**Acknowledgements.** The authors thank Dr. R. Silva Rodríguez, CIGB, for his assistance in manuscript preparation.

### References

- Ackerman AL, Giodini A, Cresswell P (2006): A role for the endoplasmic reticulum protein retrotranslocation machinery during crosspresentation by dendritic cells. *Immunity* 25, 607. doi:10.1016/j.immuni.2006.08.017
- Beaumier CM, Mathew A, Bashyam HS, Rothman AL (2008): Cross-reactive memory CD8+ T cells alter the immune response to heterologous secondary dengue virus infections in mice in a sequence-specific manner. *J. Infect. Dis.* 197, 608–617. doi:10.1086/526790
- Caruso A, Licenzi S, Corulli M, Canaris AD, De Francesco MA, Fiorentini S, Peroni L, Fallacara F, Dima F, Balsari A, Turano A (1997): Flow cytometry analysis of activation markers on stimulated T cells and their correlation with cell proliferation. *Cytometry* 17, 71. doi:10.1002/(SICI)1097-0320(19970101)27:1<71::AID-CYTO9>3.0.CO;2-O
- Cheng Y, King NG, Kesson AM (2004): Major histocompatibility complex class I (MHC-I) induction by West Nile virus: involvement of 2 signaling pathways in MHC-I up-regulation. *J. Infect. Dis.* 189, 658–668. doi:10.1086/381501
- Fazekas de St Groth B, Smith AL, Koh W, Girgis L, Cook MC, Bertolino P (1999): Carboxyfluorescein diacetate succinimidyl ester and the virgin lymphocyte: A marriage made in heaven. *Immunol. Cell Biol.* 77, 530–538. doi:10.1046/j.1440-1711.1999.00871.x
- Frome EL, Smith M, Littlefield G, Neubert R, Colyer S (1996): Statistical methods for the blood beryllium lymphocyte proliferation test. *Environ. Health Perspect.* 105, 957. doi:10.2307/3433018
- Gagnon SJ, Zeng W, Kurane I, Ennis FA (1996) : Identification of two epitopes on the dengue 4 capsid protein protein recognized by a serotype-specific and a panel of serotype-cross-reactive human CD4+ cytotoxic T-lymphocyte clones. *J. Virol.* 70, 141–147.
- Gamble J, Bethell D, Day NP, Loc PP, Phu NH, Gartside LB, Farrar JF, White NJ (2000): Age-related changes in microvascular permeability: a significant factor in the susceptibility of children to shock? *Clin. Sci. (London)* 98, 211–216. doi:10.1042/CS19990296
- Gubler DJ, Kuno G (1997): Viral pathogenesis of dengue infections. In Gubler DJ, Kuno G (Eds): *Dengue and Dengue Hemorrhagic Fever*. Wallingford England, CAB International, pp. 273–275.
- Halstead SB (1979): In vivo enhancement of dengue virus infection in rhesus monkeys by passively transferred antibody. *J. Infect. Dis.* 140, 527–533.
- Jordan GW, Merigan TC (1974): Cell-mediated immunity to varicella-zoster virus: in vitro lymphocyte responses. *J. Infect. Dis.* 125, 495–501.
- Hawke S, Stevenson PG, Freeman S, Bangham CR (1998): Long-term persistence of activated cytotoxic T lymphocytes after viral infection of the central nervous system. *J. Exp. Med.* 187, 1575. doi:10.1084/jem.187.10.1575
- Kurane I, Brinton MA, Samson AL, Ennis FA (1991): Dengue virus-specific, human CD4+ CD8- cytotoxic T cell clones: Multiple patterns of virus cross-reactivity recognised by NS3-specific T-cell clones. *J. Virol.* 65, 1823–1828.
- Lazo L, Hermida L, Zulueta A, Sánchez J, López C, Silva R, Guillén G, Guzmán MG (2007): A recombinant capsid protein from Dengue-2 induces protection in mice against homologous virus. *Vaccine* 25, 1064–1070. doi:10.1016/j.vaccine.2006.09.068
- Lechmann M, Liang TJ (2000): Vaccine development for Hepatitis C. *Semin. Liver Dis.* 20, 211–226. doi:10.1055/s-2000-9947
- Leitmeyer KC, Vaughn DW, Watts DM, Salas R, Villalobos I, Ramo C, Rico-Hesse R (1999): Dengue virus structural differences that correlate with pathogenesis. *J. Virol.* 73, 4738–4747.
- Libraty DH, Endy HS, Houg HS, Green S, Kalayanarooj S, Suntayakorn S, Chansiriwong W, Vaughn DW, Nisalak A, Ennis FA, Rothman AL (2002): Differing influences of virus burden and immune activation on disease severity in secondary dengue-3 virus infections. *J. Infect. Dis.* 185, 1213–1221. doi:10.1086/340365
- Lobigs M, Mullbacher A, Lee E (2004): Evidence that a mechanism for efficient flavivirus budding upregulates MHC class I. *Immunol. Cell Biol.* 82, 184–188. doi:10.1046/j.0818-9641.2004.01218.x
- Loke H, Bethell DB, Phuong CX, Dung M, Schneider J, White NJ, Day NP, Farrar J, Hill AV (2001): Strong HLA class I-restricted T cell response in dengue hemorrhagic fever: a double-edged sword? *J. Infect. Dis.* 184, 1369–1373. doi:10.1086/324320
- López C, Sánchez J, Hermida L, Zulueta A, Marquez G (2004) Cysteine mediated multimerization of a recombinant dengue E fragment fused to the P64k protein by immobilized metal ion affinity chromatography. *Protein Expr. Purif.* 34, 176–182. doi:10.1016/j.pep.2003.11.018
- López C, Gil L, Lazo L, Menéndez I, Marcos E, Sánchez J, Valdés I, Falcón V, de la Rosa MC, Márquez G, Guillén G, Hermida L (2009): The in vitro assembly of nucleocapsid-like particles from the purified recombinant capsid protein of dengue 2. *Arch. Virol.* 154, 695–698. doi:10.1007/s00705-009-0350-8

- Lyon AB, Parish CR (1994): Determination of lymphocytes division by flow cytometry. *J. Immunol. Methods* 171, 131–136. [doi:10.1016/0022-1759\(94\)90236-4](https://doi.org/10.1016/0022-1759(94)90236-4)
- Mannering SI, Morris JS, Jensen KP, Purcel AW, Honeyman MC, van Endert PM, Harrison LC (2003): A sensitive method for detecting proliferation of rare autoantigen-specific human T cells. *J. Immunol. Methods* 283, 173–183. [doi:10.1016/j.jim.2003.09.004](https://doi.org/10.1016/j.jim.2003.09.004)
- Marten NW, Stohlman SA, Bergmann CC (2000): Role of viral persistence in retaining CD8+ T cells within central nervous system. *J. Virol.* 74, 7903. [doi:10.1128/JVI.74.17.7903-7910.2000](https://doi.org/10.1128/JVI.74.17.7903-7910.2000)
- Mongkolsapaya J, Dejnirattisai W, Xu XN, Vasanawathana S, Tangthawornchaikul N, Chairunsri A, Sawasdivorn S, Duangchinda T, Dong T, Rowland-Jones S, Yenchtso-manus PT, McMichael A, Malasit P, Screaton G (2003): Original antigenic sin and apoptosis in the pathogenesis of dengue hemorrhagic fever. *Nat. Med.* 9, 921–927. [doi:10.1038/nm887](https://doi.org/10.1038/nm887)
- Mongkolsapaya J, Duangchinda T, Dejnirattisai W, Vasanawathana S, Avirutnan P, Jairungsri A, Khemnu N, Tangthawornchaikul N, Chotiyanwong P, Sae-Jang K, Koch M, Jones I, McMichael A, Xu X, Malasit P, Screaton G (2006): T cell response in Dengue Hemorrhagic Fever: Are cross-reactive T cells suboptimal? *J. Immunol.* 176, 3821–3829.
- Rothman AL, Kurane I, Ennis FA (1996): Multiple Specificities in the Murine CD4+ and CD8+ T-Cell Response to Dengue Virus. *J. Virol.* 70, 6540–6546.
- Simmons CP, Dong T, Chau NV, Dung NTP, Chau TNB, Thao LTT, Dung NT, Hien TT, Rowland-Jones S, Farrar J (2005): Early T-cell response to Dengue virus epitopes in Vietnamese adults with secondary Dengue virus infections. *J. Virol.* 79, 5665–5675. [doi:10.1128/JVI.79.9.5665-5675.2005](https://doi.org/10.1128/JVI.79.9.5665-5675.2005)
- Svahn A, Linde A, Thorstensson R, Karlén K, Andersson L, Gaines H (2003): Development and evaluation of a flow-cytometry assay of specific cell-mediated immune response in activated whole blood for detection of cell-mediated immunity against varicella-zoster virus. *J. Immunol. Methods* 277, 17–25. [doi:10.1016/S0022-1759\(03\)00111-X](https://doi.org/10.1016/S0022-1759(03)00111-X)
- Van der Most RG, Murali-Krishna K, Ahmed R, Strauss JH (2000): Chimeric yellow fever/dengue virus as a candidate dengue vaccine: quantitation of the dengue virus-specific CD8 T-cell response. *J. Virol.* 4, 8094–8101. [doi:10.1128/JVI.74.17.8094-8101.2000](https://doi.org/10.1128/JVI.74.17.8094-8101.2000)
- Vauhgn DW, Green S, Kalayanarooj S, Innis, BL, Nimmannitya S, Suntayakorn S, Endy TP, Raengsakulrach B, Rothman AL, Ennis FA, Nisalak A (2000): Dengue viremia titer, antibody response pattern, and virus serotype correlate with disease severity. *J. Infect. Dis.* 181, 2–9. [doi:10.1086/315215](https://doi.org/10.1086/315215)
- Venken K, Thewissen M, Helling N, Somers V, Hensen K, Rummens J-L, Stinissen P (2007): A CFSE based assay for measuring CD4+CD25+ regulatory T cell mediated suppression of auto-antigen specific and polyclonal T cell response. *J. Immunol. Methods* 322, 1–11. [doi:10.1016/j.jim.2007.01.025](https://doi.org/10.1016/j.jim.2007.01.025)
- Wang FZ, Dalh H, Ljungman P, Linde A (1999): Lymphoproliferative responses to human herpesvirus-6 variant A and variant B in healthy adults. *J. Med. Virol.* 57, 134–139. [doi:10.1002/\(SICI\)1096-9071\(199902\)57:2<134::AID-JMV8>3.0.CO;2-Q](https://doi.org/10.1002/(SICI)1096-9071(199902)57:2<134::AID-JMV8>3.0.CO;2-Q)
- Williams MA, Holmes BJ, Sun JC, Bevan MJ (2006): Developing and maintaining protective CD8+ memory T cells. *Immol. Rev.* 211, 146–153. [doi:10.1111/j.0105-2896.2006.00389.x](https://doi.org/10.1111/j.0105-2896.2006.00389.x)
- Yauch LE, Zellweger RM, Kotturi MF, Qutubuddin A, Sidney J, Peters B, Prestwood TR, Sette A, Shresta S (2009): A protective role for dengue virus-specific CD8+ cells. *J. Immunol.* 182, 4865–4873. [doi:10.4049/jimmunol.0801974](https://doi.org/10.4049/jimmunol.0801974)
- Zivny J, DeFronzo M, Jarry W, Jameson J, Cruz J, Ennis FA, Rothman AL (1999): Partial agonist effect influences the CTL response to a heterologous dengue virus serotype. *J. Immunol.* 163, 2754–2760.